0001070081-19-000020.txt : 20190307
0001070081-19-000020.hdr.sgml : 20190307
20190307213141
ACCESSION NUMBER: 0001070081-19-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190305
FILED AS OF DATE: 20190307
DATE AS OF CHANGE: 20190307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Utter Christine Marie
CENTRAL INDEX KEY: 0001707685
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35969
FILM NUMBER: 19667441
MAIL ADDRESS:
STREET 1: C/O PTC THERAPEUTICS, INC.
STREET 2: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001070081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043416587
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
BUSINESS PHONE: 9082227000
MAIL ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
FORMER COMPANY:
FORMER CONFORMED NAME: PTC THERAPEUTICS INC
DATE OF NAME CHANGE: 19980909
4
1
wf-form4_155201228629693.xml
FORM 4
X0306
4
2019-03-05
0
0001070081
PTC THERAPEUTICS, INC.
PTCT
0001707685
Utter Christine Marie
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD
NJ
07080
0
1
0
0
Principal Financial Officer
Common Stock
2019-03-05
4
S
0
1509
34.78
D
5937
D
Common Stock
2019-03-05
4
S
0
1000
35.25
D
4937
D
Common Stock
2019-03-05
4
M
0
1150
10.85
A
6087
D
Common Stock
2019-03-05
4
S
0
540
34.71
D
5547
D
Common Stock
2019-03-05
4
S
0
610
35.17
D
4937
D
Common Stock
2019-03-05
4
M
0
18750
13.10
A
23687
D
Common Stock
2019-03-05
4
S
0
9929
34.75
D
13758
D
Common Stock
2019-03-05
4
S
0
8821
35.21
D
4937
D
Common Stock
2019-03-05
4
M
0
6300
11.23
A
11237
D
Common Stock
2019-03-05
4
S
0
2760
34.70
D
8477
D
Common Stock
2019-03-05
4
S
0
3540
35.17
D
4937
D
Stock Option (Right To Buy)
10.85
2019-03-05
4
M
0
1150
0
D
2023-05-15
Common Stock
1150.0
0
D
Stock Option (Right To Buy)
13.1
2019-03-05
4
M
0
18750
13.10
D
2027-06-02
Common Stock
18750.0
6250
D
Stock Option (Right To Buy)
11.23
2019-03-05
4
M
0
6300
11.23
D
2027-01-02
Common Stock
6300.0
6300
D
Stock Option (Right To Buy)
490.8
2021-04-27
Common Stock
74.0
74
D
Stock Option (Right To Buy)
218.4
2022-01-10
Common Stock
21.0
21
D
Stock Option (Right To Buy)
27.05
2024-01-28
Common Stock
3369.0
3369
D
Stock Option (Right To Buy)
40.45
2024-09-23
Common Stock
4688.0
4688
D
Stock Option (Right To Buy)
51.0
2025-01-02
Common Stock
17800.0
17800
D
Stock Option (Right To Buy)
30.86
2026-01-03
Common Stock
11000.0
11000
D
Stock Option (Right To Buy)
18.01
2028-01-02
Common Stock
40000.0
40000
D
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
42500.0
42500
D
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
10100.0
10100
D
The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.29 to $34.98 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $35.00 to $35.60 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.29 to $34.94 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.96 to $35.40 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.06 to $34.99 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $35.00 to $35.71 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.96 to $35.44 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Currently exercisable.
This option was granted on June 2, 2017, and vests over two years, with 50% of the shares underlying the option vesting on June 2, 2018, and an additional 12.5% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on September 2, 2018.
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
Avraham S. Adler, attorney-in-fact
2019-03-07